<DOC>
	<DOCNO>NCT01094093</DOCNO>
	<brief_summary>The purpose study assess safety tolerability AMG 139 follow single subcutaneous ( SC ) intravenous ( IV ) dose administration healthy subject subject moderate severe psoriasis ( PsO ) .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics AMG 139 Healthy Subjects Subjects With Moderate Severe Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Part A Healthy Volunteers : Healthy male female nonreproductive potential subject 18 45 yearsofage Body mass index ( BMI ) 18 32 kg/m2 Normal clinically acceptable physical examination , clinical laboratory value , ECG Additional inclusion criterion apply Part B Psoriasis Subjects : Male female nonreproductive potential subject PsO 18 55 yearsofage Body mass index ( BMI ) 18 32 kg/m2 Normal clinically acceptable physical examination ( PE ) , clinical laboratory value , ECG ; clinically acceptable PE include evidence moderate severe plaque PsO Diagnosis plaque PsO least 6 month Moderate severe plaque PsO define : A minimum PASI score ≥ 10 Psoriasis involve ≥ 10 % Body Surface Area ( BSA ) Additional inclusion criterion apply Parts A Healthy Volunteers : History evidence clinically significant disorder ( include psychiatric ) , condition disease would pose risk subject safety interfere study evaluation , procedures completion ; Recent ongoing infection ( ) Underlying condition ( ) predispose subject infection History malignancy type , situ cervical cancer surgically excise nonmelanomatous skin cancer past 5 year Additional exclusion criterion apply Part B Psoriasis Subjects : History evidence clinically significant disorder ( include psychiatric ) , condition disease would pose risk subject safety interfere study evaluation , procedures completion ; Recent ongoing infection ( ) Underlying condition ( ) predispose subject infection Guttate , pustular , nonplaque form PsO Evidence skin condition PsO ( eg , eczema ) would interfere evaluation effect investigational product psoriasis History malignancy type , situ cervical cancer surgically excise nonmelanomatous skin cancer past 5 year Additional exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Amgen</keyword>
	<keyword>AMG 139</keyword>
</DOC>